Answers are grounded in this paper and cite their sources.
Background Hallmark pathway scores may capture prognostic biology in lower-grade glioma, but their added value beyond clinical and molecular factors remains uncertain. Methods We analyzed TCGA-LGG (352 patients, 87 deaths) and CGGA (561 patients, 329 deaths). Clinical Cox models were compared with models adding Hallmark pathway scores (eight selected pathways, all 50, or five components) through cross-validation and bidirectional external validation. Random expression-matched gene sets and whole-transcriptome components served as benchmarks. Results The clinical model achieved C indices of 0.85 in TCGA cross-validation, 0.75 in forward validation, and 0.82 in reverse validation. Pathway scores changed the C index by − 0.017 to + 0.015 across four primary evaluations, and no change remained significant after Holm adjustment. Five pathway components added information beyond clinical predictors in pooled analyses (χ² = 25.1, 5 df, P = 0.00013), while random sets and whole-transcriptome components provided comparable or greater information. Sixteen pathways were nominally more prognostic than matched random sets in both cohorts. Eight-pathway scores selected in one cohort were associated with survival in the other cohort without a consistent gain in C index. Conclusions Hallmark pathway scores did not consistently improve discrimination beyond clinical and molecular factors. Some pathways were more prognostic than matched random sets in both cohorts, and random-set benchmarks help separate pathway specific from generic transcriptomic information.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: